Health Archive » May, 2010

Health - May, 2010

200 articles

• 3rd Circ. Revives Suit Tying PwC To Hospital Fraud
• High Court Urged Not To Hear ERISA Preemption Case
• Teva To Close Down Maligned Sedative Propofol
• Judge OKs Class In Dendreon Securities Suit
• Costco Settles Tylenol Infant Death Suit
• Novartis Caught In Aredia, Zometa Ad Fib
• Cephalon Faces Another Provigil Pay-For-Delay Suit
• St. Jude Sues BSC To Block Noncompete Agreement
• Solvay Loses Bid To Transfer Sales Rep's FLSA Suit
• Investors Appeal Dismissal Of BSC Stent Fraud Case
• Fed. Circ. Won't Revisit Decision To Nix Applera IP Win
• Actavis To Pay $1.2M In Idaho AWP Case
• St. Vincent's Attys' Retainer Requests Face Scrutiny
• Howmedica, Wright End Knee Implant Patent Spat
• False Dietary Supplement Ads A Problem: FTC
• Hospital's Suit Over Wash. Angioplasty Rules Nixed
• USPTO Affirms Abbott Protein Patent In War With Yeda
• Teva, Teenage Girl Settle Acne Drug Blindness Suit
• FDA Crime Unit To Investigate Tylenol Recalls
• Canadian Competition And Foreign Investment Issues
• Teva Resolves Glaxo IP Suit Over Generic Combivir
• Impax Loses Bid To Toss MDL Over Generic Wellbutrin
• Celgene, Barr Resolve Spat Over Generic Thalomid
• Wyeth Seeks $1.3M In Wholesaler Recall Refund Spat
• Novartis Trial Holds Key Lessons For Attorneys
• FDA Requires Liver Risk Warning On Alli, Xenical
• Heartburn Meds Could Up Risk Of Fractures: FDA
• FDA Still Seeks Link Between J&J Recall, Complaints
• FTC Urges 2nd Circ. To Overturn Tamoxifen Precedent
• Fried Frank Reps New Mountain In $280M Covidien Deal
• Senate Bill Would Boost Dietary Supplement Oversight
• Feingold Pushes For Drug Imports, Price Negotiations
• Digitek MDL Plaintiffs Lose Class Certification Bid
• Antitrust Counts Nixed In Inmate Medical Services Suit
• Fee Disputes Erupt In Saint Vincent's Bankruptcy
• FDA Warns J&J Unit Over Faulty Sterilization Tools
• Life Tech Sues Illumina Over DNA Device Patents
• CareGroup Pays $8.5M To Settle FLSA, ERISA Suit
• NH Still Trying To Nab $110M Surplus: Malpractice Fund
• Baxter Faces New Suit Over Quaid Twins' Overdose
• Class Action Over $28.1B Novartis, Alcon Deal Axed
• Ropes & Gray Adds Jones Day Atty To Antitrust Ranks
• Genzyme Takes Shot At Watson Over Renvela ANDA
• How FDA Disclosure Proposals Would Affect Industry
• Harkin Questions FDA In Wake Of J&J Drug Recall
• Genzyme Goes After Sandoz Again Over Hectorol
• Takeda Sues Dr. Reddy's Over Generic Actos
• Retractable Wins $5M Syringe Patent Suit V. Becton
• Varney Vows Tough Reviews For Health Insurer Mergers
• Greenberg Traurig Reps Gentiva In $1B Merger
• CMS Offers Temporary Fix For Medicare 'Donut Hole'
• High Court Seeks SG's Input On Generic-Drug Liability
• Barr Squashes Fluoxetine Stabbing Death Suit
• Wyeth Sued For Off-Label Rapamune Sales
• 7th Circ. Revives Chicago Paramedics' FLSA Suit
• Genzyme To Pay $175M Over Drug Safety Violations
• Suit Says Merck Leaked Trade Secrets To IBM
• Counterclaims Dropped In Merck-Sandoz Patent Suit
• Quality Initiatives In Health Care Reform
• En Banc Rehearing Denied Over OxyContin Potency
• Whistleblowing MD Gets $23.5M In Kickbacks Deal
• Mylan's Antitrust Claims Nixed In Prilosec IP Suit
• AstraZeneca Seeks Stay Of Dr. Reddy's Fees Award
• Abbott To Buy Piramal Generics Unit For $3.7B
• Viagra Use Linked To Long-Term Hearing Loss
• New Developments Regarding Calif. Prop 64
• India, Brazil Fight Dutch Generic Drug Seizures At WTO
• Widower Hits Pfizer With Lyrica Negligence Suit
• Consumer Groups Urge 2nd Circ. To Rehear Cipro Case
• German Court Revokes GSK's Advair Patent
• Schering Wins Neutrogena Sunscreen False Ad Suit
• Brazil Clears Sanofi's $635M Medley Pharma Buy
• The FDA 'Bad Ad' Program — Us Vs. Them
• Amedisys Revives Claims Against National Century
• Braintree Loses Bid To Toss MiraLax Antitrust Suit
• King Loses Injunction Bid In Skelaxin Suit V. Sandoz
• Akin Gump Snags Jones Day Partner
• Nationwide Fixed-Pay Insurance Settlement OK'd
• Aerocrine Resolves Apieron Patent Claims In Asset Buy
• Digital Health Liability: We Are Not In Kansas Anymore!
• Ex-McKesson Chairman To Pay $2M In SEC Deal
• Novartis Slapped With $250M Verdict In Sex Bias Case
• TLC Vision Plan Approval Sparks Outcry From MMA
• Applied Fights Off Injunction But Not $4.8M Verdict
• FDA Expands Probe Into J&J Unit Tied To Recall
• France Nixes Teva Unit's Relief Bid In Plavix Case
• Dental Group's RICO Action Against Insurers Squashed
• Calif. Plaintiffs Appeal Pay-For-Delay Cipro Case
• HUD-Insured Financing For Long-Term Care Facilities
• Sagent Recalls Anti-Infection Drug Over Contamination
• $285M Will Hit Novartis 'Where It Hurts': Plaintiffs
• China Fines Simcere Unit $3.7M Over Rabies Vaccines
• AstraZeneca, Teva Reach Patent Deal Over Entocort
• Siemens Denied Patent Rehearing In Enzo DNA Spat
• Mylan Generic Infringes Sanofi's Uroxatral Patent: Judge
• 115 Calif. Suits Cut From Prempro MDL
• Cravath Reps Universal Health In $3B Psychiatric Deal
• Weil Reps Equity Firm In $294M Radiology Co. Purchase
• States Join Suit Alleging J&J Kickbacks To Omnicare
• Jury Hits Novartis With $3.4M Sex Bias Verdict
• Stryker Wins Dismissal Of Suit Over Hip Implant
• Skadden, MoFo Help Secure $4B OSI, Astellas Deal
• Fed. Circ. Shoots Down Vaccine-Autism Link Appeal
• When Is A Win A Win With Attorneys' Fees?
• Fed. Circ. Revives Cochlear Implant Patent Dispute
• Shire Takes Shot At Actavis Over Intuniv ANDA
• GE Healthcare Recalls Anesthesia Devices: FDA
• Medicis Mulls New Solodyn IP Suit Against Mylan
• Damages Claim Upheld In Gore Faulty Device Suit
• Okla. Jury Slams Allergan With $15M Botox Verdict
• Aetna Wants To Rep End Payers In Wellbutrin MDL
• Takeda Settles Diabetes Drug Patent Dispute
• Walgreen Halts Genetic Test Kit Sale Post-FDA Warning
• FDA Warns Against Swallowing Benadryl Itch Gel
• A Blow To Gene Patenting: Impact On Innovators
• Plaintiffs Firms Wage Battle Over Fees In Vioxx MDL
• NYC's Bid To Undo Health Insurance Merger Nixed
• White House Defends Insurance Mandate In Court
• Novozymes Sues Danisco Over New Enzyme Patent
• St. Vincent's Monitor Offers Plan For Malpractice Claims
• King Wins Preliminary Injunction In Skelaxin Battle
• Express Scripts' Prices Not Set In Bad Faith: 11th Circ.
• Howmedica Off Hook In Faulty Knee Replacement Suit
• Anti-Fraud Provisions In The New Health Care Law
• Pfizer Hit With Securities Suit Over Bextra Marketing
• Genzyme Board Probing Insider Stock Sales
• FDA Urges Doctors To Report Illegal Drug Pitches
• Fed. Circ. Backs IP Extension For Photocure's Metvixia
• Childhood Obesity Task Force Unveils Action Plan
• Bias Plaintiffs' Atty Says Novartis Expert Cooked Stats
• GSK To Pay $60M To Settle Avandia Suits
• Lender Squeeze, Loan Defaults Push Chem Rx To Ch. 11
• FLSA Action Takes Aim At Gentiva's Wage Plan
• Fed. Circ. Affirms Patent Extension For Levaquin
• Discovery To Buy UK's Standard Life For $209M
• Canada's New Process For Approval Of Biosimilar Drugs
• Paul Hastings Reps Korean Drug Co. In $126M GSK Deal
• Tyco Resolves Kimberly-Clark Breathing Tube IP Suit
• Immutopics Didn't Infringe Antibody Patent: Fed. Circ.
• Novartis Fingers 'Rogue Male' Workers In Closing Args.
• Merck, Glenmark Avoid Trial With Zetia Patent Deal
• 11th Circ. Affirms Expert Exclusion In Accutane Suits
• 17 More States Want In On Wyeth Medicaid Suits
• Nexium Deceptive Marketing Action Tossed
• DNA Patent In Monsanto Suit Upheld On Re-Exam
• Micro Health Latest To Settle Mannatech's Patent Suit
• Costco Experts Nixed In Tylenol Infant Death Case
• Bill Would Screen More Chemicals In Drinking Water
• A Road Map To The Electronic Health Records Program
• Teva, Baxter Hit With $500M Damages In Hepatitis Case
• Watson Gets License From Teva As Part Of Settlement
• Divided Fed. Circ. Nixes Rehearing Of Mirapex Spat
• Drug Mart Tallman, Purdue Settle In OxyContin MDL
• Feinstein Calls For Inquiry Into Anthem Rate Hike Errors
• TLC Vision Wins Confirmation Of Ch. 11 Plan
• Simpson Thatcher To Help HCA Go Public Again
• 'DNA: Not Patentable Subject Matter' — Counterpoint
• Medicis, Ranbaxy Forge Pact For Solodyn Generic
• Utah Sues Over Off-Label Seroquel, Risperdal
• Plaintiffs Renew Schering Off-Label Marketing Claims
• Novartis Sex Bias Plaintiffs Draw Ire Over Witness
• USPTO Bearing Down On Backlog: Deputy Director
• Skadden Advises Endo On $223M HealthTronics Deal
• Health Partners, Medica Drop OxyContin Antitrust Suit
• Lilly Redoubles Fight Against Watson Evista Generic
• Xenomics, Sequenom To Arbitrate $300M Contract Spat
• House Panel To Probe Children's Tylenol Recall
• Covidien's Restoril Dose Patent Deemed Obvious
• Legislating Break Time For Nursing Mothers
• Dr. Reddy's Prilosec Fees Bid Sends Judge Reeling
• Novartis Nears End Of Its Case In Sex Bias Trial
• Merck Prevails In Bellwether Fosamax Case
• ERISA Action Against Baxter Tossed Out
• Leahy Revives Insurance Antitrust Exemption Repeal
• $5B Early Retirement Program Gets Early Start
• Weil, Wilson Advise On $213M Bard, SenoRx Merger
• Qui Tam Kickback Suit Against Stryker Booted
• J&J Plant Halts Production After FDA Finds Bacteria
• Lilly Targets Watson Over Osteoporosis Drug ANDA
• Nestle, Alcon Shareholders Reach Deal In Merger Suit
• MMSEA Reporting And Reimbursement Requirements
• DOJ Hits St. Jude With Demand Over Defibrillators
• Off-Label Marketing Suit Costs Novartis $72M
• Wyeth Drums For New Prempro Trial After $58M Hit
• FDA To Probe Prostate Cancer Drug Class
• HHS Backs 'High-Risk' Pools Despite Opposition
• Baxter Told To Recall, Destroy 200K Infusion Pumps
• Wyeth's Bid To Extend Cattle Drug Patent Trampled
• Greenberg Escapes Surgeons' $10M Malpractice Suit
• Hospital Co. Hit With Class Action Over Meal Breaks
• USPTO Panel Rejects Human Stem Cell Patent
• Ill. Toughens Up Whistleblower Protection Act
• AstraZeneca Initiates 9 IP Suits Over Crestor ANDAs
• High Court Rebuffs Bayer Bid To Revive Yasmin Patent
• J&J Unit Recalls Children's Tylenol, Other Drugs
• CVS Asst. Managers Seek Conditional Cert. In OT Suit
• America Service Settles Stock Fraud Action For $15M
• Pfizer Fails To Bar Evidence In Neurontin Suicide Suit
• High Court Won't Hear Pfizer Shareholder Suit
• 3 Myths Of In-House Attorney-Client Privilege